Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
MetadataShow full item record
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B isoform (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elía et al., p. 866.
Endocrine control mechans
License start date
Clinical Cancer Research, 2022, pp. CCR-22-3374 -
AMER ASSOC CANCER RESEARCH